Santen and US ophthalmic company Eyevance enter into share purchase agreement

Since inception in 2017, Eyevance develops and commercializes topical ophthalmic products targeting the ocular surface and anterior segment. Within this area of focus, Eyevance currently offers anti-inflammatory, anti-allergic, The post Santen and US ophthalmic company Eyevance enter into share purchase agreement appeared first on Pharmaceutical Business review.

AstraZeneca acquires Dogma’s oral PCSK9 inhibitor programme

The pharma major plans to advance the PCSK9 inhibitor programme into clinical development for dyslipidaemia and familial hypercholesterolemia in 2021. Dyslipidaemia is a condition in which there is The post AstraZeneca acquires Dogma’s oral PCSK9 inhibitor programme appeared first on Pharmaceutical Business review.

Moderna, Chiesi collaborate to develop mRNA therapeutics for pulmonary arterial hypertension

PAH is a progressive disorder characterized by high blood pressure in the arteries of the lungs with concomitant right heart failure2. There is an unmet medical need for The post Moderna, Chiesi collaborate to develop mRNA therapeutics for pulmonary arterial hypertension appeared first on Pharmaceutical Business review.

Dr. Reddy’s, RDIF partner to supply 100 million doses of Sputnik V vaccine in India

As part of the partnership, RDIF will supply 100 million doses of the vaccine to Dr. Reddy’s, after securing regulatory approval in India. Developed by the Gamaleya National The post Dr. Reddy’s, RDIF partner to supply 100 million doses of Sputnik V vaccine in India appeared first on Pharmaceutical Business review.

CuraSen doses first subjects in phase 1 trial of CST-2032

CST-2032 is a brain-permeant, selective adrenoceptor modulator designed to target key receptors in cortical and limbic regions of the brain that are no longer optimally innervated in patients The post CuraSen doses first subjects in phase 1 trial of CST-2032 appeared first on Pharmaceutical Business review.

Gilead gets FDA breakthrough therapy status for magrolimab in MDS

Magrolimab is an investigational monoclonal antibody, which has been developed to act against CD47 and macrophage checkpoint inhibitor. It is being developed in various hematologic and solid tumour The post Gilead gets FDA breakthrough therapy status for magrolimab in MDS appeared first on Pharmaceutical Business review.

Melior Pharmaceuticals awarded grant for advancing pulmonary therapeutic in Covid-19 phase 2 clinical trial

The planned study is intended to recruit 428 subjects who were recently diagnosed with COVID-19, have early symptoms, but are not hospitalized. Tolimidone is expected to significantly mitigate The post Melior Pharmaceuticals awarded grant for advancing pulmonary therapeutic in Covid-19 phase 2 clinical trial appeared first on Pharmaceutical Business review.

Takeda inaugurates new R&D cell therapy manufacturing facility in US

Situated at the company’s R&D headquarters in Boston, the new facility offers end-to-end research and development services to advance the development of next-generation cell therapies. The new R&D The post Takeda inaugurates new R&D cell therapy manufacturing facility in US appeared first on Pharmaceutical Business review.

Daiichi Sankyo initiates phase 2 study of patritumab deruxtecan in advanced colorectal cancer

Standard treatment options for patients with advanced or metastatic colorectal cancer include surgery when possible, chemotherapy with or without targeted therapy, and radiation therapy. However, many patients with The post Daiichi Sankyo initiates phase 2 study of patritumab deruxtecan in advanced colorectal cancer appeared first on Pharmaceutical Business review.

HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19

HFB30132A is said to have been discovered, engineered, and developed in less than six months by the US-based HiFiBiO Therapeutics. The company said that its partnership with ABL The post HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19 appeared first on Pharmaceutical Business review.